文献速递淋巴瘤造血干细胞移植与细胞治疗

复发难治弥漫大B细胞淋巴瘤CAR-T治疗后早期进展的预测因素

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

该研究分析116例接受商业CAR-T(axi-cel 49例,tisa-cel 67例)的复发/难治弥漫大B细胞淋巴瘤患者,中位随访8.2个月,55例治疗失败,其中27例(49%)为早期进展。多因素分析显示决策时LDH升高和结外 sites≥2,以及治疗时CRP升高、结外 sites≥2和TMTV>80 mL是早期进展的预测因素。

要点

  • 决策时LDH升高和结外 sites≥2预测早期进展。
  • 治疗时CRP升高、结外 sites≥2和TMTV>80 mL也预测早期进展。
  • 中位随访8.2个月,49%的治疗失败为早期进展。

核心结论

  • 决策时和治疗时结外受累≥2处及淋巴瘤负荷(LDH、TMTV)是早期进展的危险因素。

研究设计与样本

  • 回顾性分析116例接受商业CAR-T(axi-cel 49例,tisa-cel 67例)的复发/难治弥漫大B细胞淋巴瘤患者。
  • 在决策时和治疗时分析患者特征,并测量治疗时总代谢肿瘤体积(TMTV)。

主要发现

  • 中位随访8.2个月,55例治疗失败,其中27例(49%)为早期进展。
  • 估计12个月无进展生存率47.2%(95%CI 38.0-58.6),总生存率67.0%(95%CI 57-79)。
  • 单因素分析显示ECOG PS≥2、III/IV期、结外 sites≥2、LDH升高、CRP升高、高IPI(决策时和治疗时)、治疗时CRP升高、大包块和高TMTV是PFS和OS的危险因素。
  • 多因素分析显示决策时LDH升高和结外 sites≥2,以及治疗时CRP升高、结外 sites≥2和TMTV>80 mL预测PFS、早期进展和OS。

关键数值与推荐

  • 早期进展定义为输注后第一个月内进展。
  • 多因素分析中TMTV>80 mL为治疗时的预测阈值。

临床怎么用

  • 在CAR-T决策时和治疗时评估结外 sites数目、LDH、CRP和TMTV有助于识别早期进展高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures usually occur early after infusion. The purpose of our study was to identify factors that may predict failure, particularly early progression (EP), within the first month after infusion. Characteristics of 116 patients were analyzed at the time of decision (TD) to use commercial CAR (axicabtagene ciloleucel, n = 49; tisagenlecleucel n = 67) and at the time of treatment (TT), together with total metabolic tumor volume (TMTV) at TT. With a median follow-up of 8.2 months, 55 patients failed treatment; 27 (49%) were early progressors. The estimated 12-month progression-free survival (PFS) and overall survival (OS) were 47.2% (95% confidence interval [CI], 38.0-58.6) and 67.0% (95% CI, 57-79), respectively. Univariate analyses for PFS and OS identified Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥2, stage III/IV disease, extranodal (EN) sites ≥2, elevated lactate dehydrogenase (LDH), increased C-reactive protein (CRP), high International Prognostic Index at TD and at TT, as well as increased CRP, bulky mass, and high TMTV at TT, as risk factors. Multivariate analyses for PFS, EP, and OS identified elevated LDH and EN sites ≥2 at TD and the same predictors at TT (ie, increased CRP, EN sites ≥2, and TMTV >80 mL). In summary, risk factors identified for early progression at TD and at TT were EN involvement (≥2 sites) and lymphoma burden (LDH, TMTV).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020. PMID: 33180899. doi:10.1182/bloodadvances.2020003001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。